Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice

Brain

Volumn 135, Issue 4, 2012, Pages 1081-1101

  Klooster, Rinse ^a   Plomp, Jaap J ^a   Huijbers, Maartje G ^a,b   Niks, Erik H ^a   Straasheijm, Kirsten R ^a   Detmers, Frank J ^c   Hermans, Pim W ^c   Sleijpen, Kevin ^c   Verrips, Aad ^d   Losen, Mario ^b   Martinez Martinez, Pilar ^b   De Baets, Marc H ^b,e   Van Der Maarel, Silvre M ^a   Verschuuren, Jan J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c BAC BV   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

autoantibodies; electrophysiology; muscle specific kinase; myasthenia gravis; neuromuscular junction

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CASE REPORT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IN VITRO STUDY; MOUSE; MUSCLE FATIGUE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SYNAPSE;

EID: 84860155499     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws025     Document Type: Article

References (75)

1. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.
2. Apel ED, Roberds SL, Campbell KP, Merlie JP. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron 1995; 15: 115-26.
3. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987; 166: 1351-61. (Pubitemid 18051427)
4. Burrone J, Murthy VN. Synaptic gain control and homeostasis. Curr Opin Neurobiol 2003; 13: 560-7. (Pubitemid 37431183)
5. Cartaud A, Strochlic L, Guerra M, Blanchard B, Lambergeon M, Krejci E, et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 2004; 165: 505-15. (Pubitemid 38679616)
6. Cole RN, Ghazanfari N, Ngo ST, Gervasio OL, Reddel SW, Phillips WD. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010; 588: 3217-29.
7. Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63: 782-9. (Pubitemid 351945537)
8. Cull-Candy SG, Miledi R, Trautmann A, Uchitel OD. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol 1980; 299: 621-38. (Pubitemid 10113776)
9. Davis GW, Bezprozvanny I. Maintaining the stability of neural function: a homeostatic hypothesis. Annu Rev Physiol 2001; 63: 847-69. (Pubitemid 32304339)
10. Eken T. Spontaneous electromyographic activity in adult rat soleus muscle. J Neurophysiol 1998; 80: 365-76. (Pubitemid 28326269)
11. Elmqvist D, Hofmann WW, Kugelberg J, Quastel DM. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol 1964; 174: 417-34.
12. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977; 52: 267-80. (Pubitemid 8113467)
13. Engel AG, Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci 1971; 183: 46-63.
14. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126: 2304-11. (Pubitemid 37432373)
15. Farrugia ME, Kennett RP, Newsom-Davis J, Hilton-Jones D, Vincent A. Single-fiber electromyography in limb and facial muscles in musclespecific kinase antibody and acetylcholine receptor antibody myasthenia gravis. Muscle Nerve 2006a; 33: 568-70.
16. Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006b; 129: 1481-92. (Pubitemid 43999381)
17. Fiekers JF. Interactions of edrophonium, physostigmine and methanesulfonyl fluoride with the snake end-plate acetylcholine receptor-channel complex. J Pharmacol Exp Ther 1985; 234: 539-49. (Pubitemid 15240528)
18. Guptill JT, Sanders DB, Evoli A. Anti-musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44: 36-40.
19. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131: 1197-208.
20. Harris JB, Ribchester RR. The relationship between end-plate size and transmitter release in normal and dystrophic muscles of the mouse. J Physiol 1979; 296: 245-65.
21. Hesser BA, Henschel O, Witzemann V. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol Cell Neurosci 2006; 31: 470-80. (Pubitemid 43361926)
22. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8. (Pubitemid 32224355)
23. Ip FC, Glass DG, Gies DR, Cheung J, Lai KO, Fu AK, et al. Cloning and characterization of muscle-specific kinase in chicken. Mol Cell Neurosci 2000; 16: 661-73. (Pubitemid 32001313)
24. Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006; 175: 107-17. (Pubitemid 43765734)
25. Kaja S, van de Ven RC, van Dijk JG, Verschuuren JJ, Arahata K, Frants RR, et al. Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a-mutant mouse rolling Nagoya. Eur J Neurosci 2007; 25: 2009-20. (Pubitemid 46581725)
26. Kawakami Y, Ito M, Hirayama M, Sahashi K, Ohkawara B, Masuda A, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77: 1819-26.
27. Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135: 334-42.
28. Linnoila J, Wang Y, Yao Y, Wang ZZ. A mammalian homolog of Drosophila tumorous imaginal discs, Tid1, mediates agrin signaling at the neuromuscular junction. Neuron 2008; 60: 625-41.
29. Magby JP, Bi C, Chen ZY, Lee FS, Plummer MR. Single-cell characterization of retrograde signaling by brain-derived neurotrophic factor. J Neurosci 2006; 26: 13531-6. (Pubitemid 46026485)
30. Magleby KL, Stevens CF. A quantitative description of end-plate currents. J Physiol 1972; 223: 173-97.
31. Martinez-Martinez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, et al. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol 2007; 170: 644-57. (Pubitemid 47339401)
32. Martinez-Martinez P, Phernambucq M, Steinbusch L, Schaeffer L, Berrih-Aknin S, Duimel H, et al. Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiol Dis 2009; 35: 14-23.
33. Maselli RA, Leung C. Analysis of anticholinesterase-induced neuromuscular transmission failure. Muscle Nerve 1993; 16: 548-53. (Pubitemid 23138104)
34. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004; 55: 580-4. (Pubitemid 38391977)
35. McLachlan EM, Martin AR. Non-linear summation of end-plate potentials in the frog and mouse. J Physiol 1981; 311: 307-24. (Pubitemid 11166922)
36. Milone M, Wang HL, Ohno K, Prince R, Fukudome T, Shen XM, et al. Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor epsilon subunit. Neuron 1998; 20: 575-88. (Pubitemid 28153086)
37. Murray LM, Gillingwater TH, Parson SH. Using mouse cranial muscles to investigate neuromuscular pathology in vivo. Neuromuscul Disord 2010; 20: 740-3.
38. Niks EH, Kuks JB, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66: 1772-4. (Pubitemid 43964645)
39. Niks EH, Kuks JB, Wokke JH, Veldman H, Bakker E, Verschuuren JJ, et al. Pre-and postsynaptic neuromuscular junction abnormalities in musk myasthenia. Muscle Nerve 2010; 42: 283-8.
40. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008; 195: 151-6.
41. Nirula A, Glaser SM, Kalled SL, Taylora FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23: 119-24.
42. Noakes PG, Gautam M, Mudd J, Sanes JR, Merlie JP. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin laminin beta 2. Nature 1995; 374: 258-62.
43. Oh SJ, Hatanaka Y, Hemmi S, Young AM, Scheufele ML, Nations SP, et al. Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 2006; 33: 500-4.
44. Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007; 14: 1029-34. (Pubitemid 47300778)
45. Pilgram GS, Potikanond S, Baines RA, Fradkin LG, Noordermeer JN. The roles of the dystrophin-associated glycoprotein complex at the synapse. Mol Neurobiol 2010; 41: 1-21.
46. Plomp JJ, Van Kempen GT, De Baets MB, Graus YM, Kuks JB, Molenaar PC. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 1995; 37: 627-36.
47. Plomp JJ, Van Kempen GT, Molenaar PC. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin- treated rats. J Physiol 1992; 458: 487-99. (Pubitemid 23024605)
48. Punga AR, Flink R, Askmark H, Stalberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006; 34: 111-5.
49. Punga AR, Lin S, Oliveri F, Meinen S, Ruegg MA. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 2011; 230: 207-17.
50. Regehr WG, Carey MR, Best AR. Activity-dependent regulation of synapses by retrograde messengers. Neuron 2009; 63: 154-70.
51. Rock B, Martins CR, Theofilopoulos AN, Balderas RS, Anhalt GJ, Labib RS, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320: 1463-9. (Pubitemid 19143712)
52. Sandrock AW Jr, Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE, et al. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 1997; 276: 599-603. (Pubitemid 27193685)
53. Schrö der K, Linker RA, Gold R. Plasmapheresis for neuroinflammatory disorders. Clin Exp Neuroimmunol 2010; 1: 95-102.
54. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004; 62: 1945-50. (Pubitemid 38738201)
55. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006; 116: 1016-24.
56. Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005; 57: 289-93. (Pubitemid 40179868)
57. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995; 154: 180-91.
58. Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007; 299: 1-8. (Pubitemid 46723573)
59. Sons MS, Busche N, Strenzke N, Moser T, Ernsberger U, Mooren FC, et al. alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 2006; 138: 433-46.
60. Stacy S, Gelb BE, Koop BA, Windle JJ, Wall KA, Krolick KA, et al. Split tolerance in a novel transgenic model of autoimmune myasthenia gravis. J Immunol 2002; 169: 6570-9. (Pubitemid 36903510)
61. Strochlic L, Cartaud A, Cartaud J. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions. Bioessays 2005; 27: 1129-35. (Pubitemid 43076139)
62. ter Beek WP, Martinez-Martinez P, Losen M, de Baets MH, Wintzen AR, Verschuuren JJ, et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am J Pathol 2009; 175:1536-44.
63. Tsiamalos P, Kordas G, Kokla A, Poulas K, Tzartos SJ. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol 2009; 16: 925-30.
64. Tsujihata M, Yoshimura T, Satoh A, Kinoshita I, Matsuo H, Mori M, et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989; 39: 1359-63. (Pubitemid 19246812)
65. Valenzuela DM, Stitt TN, DiStefano PS, Rojas E, Mattsson K, Compton DL, et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 1995; 15: 573-84.
66. van der Neut Kolfschoten KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317: 1554-7. (Pubitemid 47417435)
67. van der Plas MC, Pilgram GS, Plomp JJ, de Jong A, Fradkin LG, Noordermeer JN. Dystrophin is required for appropriate retrograde control of neurotransmitter release at the Drosophila neuromuscular junction. J Neurosci 2006; 26: 333-44. (Pubitemid 43089547)
68. Verschuuren JJ, Palace J, Gilhus NE. Clinical aspects of myasthenia explained. Autoimmunity 2010; 43: 344-52.
69. Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008; 1132: 84-92. (Pubitemid 351841363)
70. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982; 49: 257-65. (Pubitemid 12097352)
71. Wood SJ, Slater CR. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast-and slow-twitch muscles. J Physiol 1997; 500 (Pt 1): 165-76. (Pubitemid 27165840)
72. Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol 2001; 64: 393-429. (Pubitemid 32244140)
73. Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development 2010; 137: 1017-33.
74. Xu K, Jha S, Hoch W, Dryer SE. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 2006; 143: 655-9. (Pubitemid 44751373)
75. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron 2008; 60: 285-97.